3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
Advertisement
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
ANTX AN2 Therapeutics Inc
283
$2.03
$0.06
(2.87%)
| Watchers | 283 |
| 52-Wk Low | $1.92 |
| 52-Wk High | $22.22 |
| Market Cap | $60.55M |
| Volume | 57,037.00 |
| 52-Wk High | $22.22 |
| 52-Wk Low | $1.92 |
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific HighlightsBusiness Wire • 25 days ago
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
AN2 Therapeutics, Inc. (ANTX) has disclosed a new risk, in the Innovation / R&D category. AN2 Therapeutics, Inc. faces significant business risk as...
AN2 Therapeutics GAAP EPS of -$0.57 beats by $0.17...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
The post ANTX...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today...
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results PR Newswire DURHAM...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of...
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AN2 Therapeutics, Inc. ( AN2 or the Company ) (NASDAQ: ANTX). Such investors are...